Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford(South Australia Pathology), Timothy P. Hughes(Royal Adelaide Hospital), Linda Fletcher(Princess Alexandra Hospital), Nicola D. Roberts(European Bioinformatics Institute), Haley Altamura(South Australia Pathology), Leanne Purins(South Australia Pathology), Zoe Donaldson(South Australia Pathology), David M. Ross(Flinders Medical Centre), Jodi Braley(South Australia Pathology), Bronte A. Jamison(South Australia Pathology), Alexandra L. Yeoman(South Australia Pathology), Stuart Phillis(South Australia Pathology), Jasmina Georgievski(South Australia Pathology), John F. Seymour(The Royal Melbourne Hospital), Andrew Grigg(The Royal Melbourne Hospital), David T Yeung(Royal Adelaide Hospital), Mary Leong(South Australia Pathology), Wendy T Parker(University of South Australia)
Cited by 198
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k